Form 4: Anixa Biosciences Director Exercises Stock Options
SEC Form 4 Filing
Lewis H. Titterton Jr., a director of Anixa Biosciences, exercised stock options to acquire 16,000 shares of common stock at $2.575 per share on October 22, 2024.
Summary
- On October 22, 2024, Lewis H. Titterton Jr., a director of Anixa Biosciences Inc., exercised employee stock options.
- This transaction involved the acquisition of 16,000 shares of common stock at a price of $2.575 per share.
- Following the transaction, Titterton directly owns 912,334 shares of Anixa Biosciences Inc.
- The stock options were granted on January 2, 2015, and are exercisable until January 2, 2025.
Sentiment
Score: 5
Explanation: Neutral. This is a standard regulatory filing related to the exercise of stock options by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 01/02/2015 | Date of stock option grant. |
| 10/22/2024 | Date of transaction (exercise of stock options). |
| 10/23/2024 | Date of signature on the Form 4 filing. |
| 01/02/2025 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.